March 7, 2018 / 1:18 PM / in 9 months

BRIEF-Ultragenyx Posts Positive Topline Results Of Phase 1/2 Clinical Study Of Investigational Gene Therapy DTX301

March 7 (Reuters) - Ultragenyx Pharmaceutical Inc:

* ULTRAGENYX ANNOUNCES POSITIVE TOPLINE RESULTS AND DMC REVIEW FROM FIRST COHORT OF PHASE 1/2 CLINICAL STUDY OF DTX301, AN INVESTIGATIONAL GENE THERAPY IN ORNITHINE TRANSCARBAMYLASE (OTC) DEFICIENCY

* ULTRAGENYX PHARMACEUTICAL INC - ‍COHORT 2 PATIENT ENROLLMENT TO BEGIN IN MARCH 2018; DATA EXPECTED IN SECOND HALF OF 2018​

* ULTRAGENYX PHARMACEUTICAL INC - ‍UREAGENESIS NORMALIZED IN ONE PATIENT AND FURTHER INCREASED BY 24 WEEKS​

* ULTRAGENYX - ‍IN DTX301 COHORT 1, AS OF FEB 15, THERE WERE NO INFUSION-RELATED ADVERSE EVENTS & NO SERIOUS ADVERSE EVENTS REPORTED​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below